Why is enrollment in potentially life-extending cancer trials so low?

Written by Ilana Landau, Editor

Researchers have analyzed data on over 12 million individuals with various cancers and determined that, following cancer diagnosis, enrollment in clinical trials as the first course of treatment is as low as 0.1%, despite the potential gain in life expectancy that trial participation may confer. Researchers from the Penn State Cancer Institute (PA, USA) have analyzed data on more than 12 million individuals, with 46 different cancers, and determined enrollment in clinical trials as the first course of treatment following cancer diagnosis to be as low as 0.1%, despite the potential gain in life expectancy that trial participation may confer....

To view the full article, please register now for access

It's completely free